Loading...

Kevin Shannon, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentPediatrics
Address1450 Third St
San Francisco CA 94158
Phone415-476-7932
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1988Pediatric Hematology/Oncology
    UT Southwestern, DallasResidency 1982Pediatrics

    Collapse Research 
    Collapse Research Activities and Funding
    In Vivo Functional Analysis of Chromosome 7q22 Deletions in Myeloid Malignancies
    NIH/NCI R01CA216352May 22, 2017 - Apr 30, 2022
    Role: Principal Investigator
    Developmental and HyperActive Ras Tumor SPORE
    NIH/NCI U54CA196519Sep 1, 2015 - Aug 31, 2020
    Role: Co-Principal Investigator
    Selectively Targeting Oncogenic NRAS in Cancer
    NIH/NCI R01CA193994Apr 1, 2015 - Mar 31, 2020
    Role: Principal Investigator
    (PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers
    NIH/NCI R01CA180037Sep 17, 2013 - Jul 31, 2017
    Role: Principal Investigator
    Research Training in Childhood Cancer
    NIH/NCI T32CA128583Jul 1, 2007 - Aug 30, 2022
    Role: Principal Investigator
    Role of PTPN11 Mutations in Myeloid Leukemogenesis
    NIH/NCI R01CA104282May 1, 2004 - Feb 29, 2012
    Role: Principal Investigator
    NNFF CONSORTIUM:MOLECULAR AND CELL BIOLOGY OF NF1&NF2
    NIH/NINDS R13NS040313May 24, 2000 - Apr 30, 2001
    Role: Principal Investigator
    Mouse Models of Myeloid Leukemia
    NIH/NCI U01CA084221Sep 30, 1999 - Mar 31, 2010
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    MARK I, RESEARCH IRRADIATOR WITH CESIUM 137 SOURCE
    NIH/NCRR S10RR013781Jan 14, 1999 - Jun 1, 2000
    Role: Principal Investigator
    Translational Investigation of KRas & NF1 in Myeloid Leukemia
    NIH/NCI R37CA072614Feb 15, 1997 - Jan 31, 2017
    Role: Principal Investigator
    Translational Investigation of NF1 in Myeloid Luekemia
    NIH/NCI R01CA072614Feb 15, 1997 - Jan 31, 2007
    Role: Principal Investigator
    Etiology of Alkylator-Induced Myeloid Leukemia
    NIH P01CA040046Sep 1, 1985 - Aug 31, 2013
    Role: Co-Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator
    PEDIATRIC CLINICAL RESEARCH CENTER
    NIH/NCRR M01RR001271Dec 1, 1981 - Mar 31, 2007
    Role: Co-Investigator
    Medical Scientist Training Program
    NIH/NIGMS T32GM007618Jul 1, 1978 - Jun 30, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gallotti RG, Shannon KM, Moore JP. Subvalvular catheter ablation of the cavotricuspid isthmus in a patient with Ebstein's anomaly and tricuspid valve replacement. HeartRhythm Case Rep. 2017 Jul; 3(7):336-339. PMID: 28748139.
      View in: PubMed
    2. Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell. 2017 Feb 23; 168(5):817-829.e15. PMID: 28215705.
      View in: PubMed
    3. Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313. PMID: 28191887.
      View in: PubMed
    4. Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica. 2016 Oct; 101(10):1190-1199. PMID: 27418650.
      View in: PubMed
    5. White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nat Commun. 2016 Feb 08; 7:10647. PMID: 26854029; PMCID: PMC4748120.
    6. Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM. KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Rep. 2016 Feb 16; 14(6):1448-1461. PMID: 26854235; PMCID: PMC4758864 [Available on 02/16/17].
    7. Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015 Jul 20; 4. PMID: 26193121; PMCID: PMC4569895.
    8. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015 May; 47(5):539-43. PMID: 25822087; PMCID: PMC4414804.
    9. Shannon KM. CCR4 drives ATLL jail break. J Exp Med. 2014 Dec 15; 211(13):2485. PMID: 25512583; PMCID: PMC4267231.
    10. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55. PMID: 25361812; PMCID: PMC4271180.
    11. Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood. 2014 Nov 20; 124(22):3274-83. PMID: 25316678; PMCID: PMC4239336.
    12. Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 2014 Sep 25; 513(7519):512-6. PMID: 25043004; PMCID: PMC4213126.
    13. Shannon K, Hermiston M. A(nother) RAF mutation in LCH. Blood. 2014 May 15; 123(20):3063-5. PMID: 24832939; PMCID: PMC4023415.
    14. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65. PMID: 24794707; PMCID: PMC4206212.
    15. Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood. 2014 Feb 27; 123(9):1426-7. PMID: 24578498; PMCID: PMC3938154.
    16. North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD. Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer. 2014 Jan 05; 14:6. PMID: 24386979; PMCID: PMC3898384.
    17. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 03; 6(304):ra105. PMID: 24300897; PMCID: PMC4117477.
    18. Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 2013 Dec 05; 504(7478):143-147. PMID: 24284627; PMCID: PMC4128640.
    19. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
    20. Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 2013 Aug 29; 122(9):1610-20. PMID: 23818547; PMCID: PMC3953014.
    21. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013 Sep; 3(9):993-1001. PMID: 23733505; PMCID: PMC3770749.
    22. Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood. 2013 Jun 13; 121(24):4884-93. PMID: 23637129; PMCID: PMC3682340.
    23. Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci Signal. 2013 Mar 26; 6(268):ra21. PMID: 23532335; PMCID: PMC3737252.
    24. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan; 123(1):335-9. PMID: 23221337; PMCID: PMC3533281.
    25. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012 Oct 25; 120(17):3397-406. PMID: 22898602; PMCID: PMC3482854.
    26. Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis. Blood. 2012 Apr 12; 119(15):3374-6. PMID: 22500049.
      View in: PubMed
    27. Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. 2012 Jan 26; 119(4):1032-5. PMID: 22144181; PMCID: PMC3271715.
    28. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011 Mar 30; 3(76):76ra27. PMID: 21451123; PMCID: PMC3265440.
    29. Shannon K, Li Q. Oncogenic Ras scales the ALPS. Blood. 2011 Mar 10; 117(10):2747-8. PMID: 21393497.
      View in: PubMed
    30. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011 Apr 21; 117(16):4253-61. PMID: 21398220; PMCID: PMC3087477.
    31. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 2011 Jan 01; 71(1):106-15. PMID: 21199799; PMCID: PMC3077533.
    32. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011 Feb 10; 117(6):2022-32. PMID: 21163920; PMCID: PMC3056645.
    33. Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. N Engl J Med. 2010 Dec 16; 363(25):2460-1. PMID: 21067376; PMCID: PMC4117480.
    34. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med. 2010 Nov 22; 207(12):2581-94. PMID: 21059853; PMCID: PMC2989761.
    35. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010 Jul 01; 24(13):1389-402. PMID: 20595231; PMCID: PMC2895198.
    36. Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood. 2010 Jun 03; 115(22):4524-32. PMID: 20233966; PMCID: PMC2881500.
    37. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5106-11. PMID: 20194733; PMCID: PMC2841878.
    38. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010 Jan; 152A(1):4-24. PMID: 20014119; PMCID: PMC4051786.
    39. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009 Sep 17; 461(7262):411-4. PMID: 19727076; PMCID: PMC4119783.
    40. Shannon K, Loh M. Cancer: More than kin and less than kind. Nature. 2009 Aug 13; 460(7257):804-7. PMID: 19675635.
      View in: PubMed
    41. Braun BS, Shannon K. The SPS affair: a complex tale of illicit proliferation. Cancer Cell. 2009 Aug 04; 16(2):87-8. PMID: 19647218.
      View in: PubMed
    42. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009 Aug 27; 114(9):1859-63. PMID: 19571318; PMCID: PMC2738571.
    43. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59. PMID: 19296721; PMCID: PMC2656550.
    44. Wong JC, Le Beau MM, Shannon K. Tumor suppressor gene inactivation in myeloid malignancies. Best Pract Res Clin Haematol. 2008 Dec; 21(4):601-14. PMID: 19041599.
      View in: PubMed
    45. Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood. 2009 Jan 29; 113(5):1075-85. PMID: 18948576; PMCID: PMC2635073.
    46. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008 Oct 07; 14(4):335-43. PMID: 18835035; PMCID: PMC2647559.
    47. Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood. 2009 Feb 12; 113(7):1455-63. PMID: 18818388; PMCID: PMC2644073.
    48. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008 Apr 15; 14(8):2249-52. PMID: 18413813.
      View in: PubMed
    49. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008 May; 40(5):600-8. PMID: 18372904; PMCID: PMC2410301.
    50. Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat. 2008 Feb; 29(2):232-9. PMID: 17979197.
      View in: PubMed
    51. Shannon KM, Le Beau MM. Cancer: hay in a haystack. Nature. 2008 Jan 17; 451(7176):252-3. PMID: 18202630.
      View in: PubMed
    52. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008 Feb 01; 111(3):1044-53. PMID: 18000167; PMCID: PMC2214754.
    53. Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol. 2007 Nov; 27(22):7765-70. PMID: 17875937; PMCID: PMC2169154.
    54. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes Dev. 2007 Aug 15; 21(16):1989-92. PMID: 17699748.
      View in: PubMed
    55. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007 Apr; 7(4):295-308. PMID: 17384584.
      View in: PubMed
    56. Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD. Abnormal hematopoiesis in Gab2 mutant mice. Blood. 2007 Jul 01; 110(1):116-24. PMID: 17374739; PMCID: PMC1896106.
    57. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007 Feb; 17(1):15-22. PMID: 17208427.
      View in: PubMed
    58. Shannon K, Bollag G. Sending out an SOS. Nat Genet. 2007 Jan; 39(1):8-9. PMID: 17192780.
      View in: PubMed
    59. Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007 May 01; 109(9):3945-52. PMID: 17192389; PMCID: PMC1874575.
    60. Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 2007 Feb 15; 109(4):1687-91. PMID: 17090653; PMCID: PMC1794059.
    61. Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle. 2006 Aug; 5(15):1607-11. PMID: 16921267.
      View in: PubMed
    62. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006 Sep 15; 108(6):2041-4. PMID: 16720837; PMCID: PMC1895533.
    63. Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood. 2006 Sep 01; 108(5):1684-9. PMID: 16690971; PMCID: PMC1895516.
    64. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006 May 01; 46(5):579-85. PMID: 16261595.
      View in: PubMed
    65. Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest. 2006 Apr; 116(4):847-52. PMID: 16585951; PMCID: PMC1421367.
    66. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006 Jun 01; 107(11):4508-13. PMID: 16493009; PMCID: PMC1895800.
    67. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006 Mar; 38(3):331-6. PMID: 16474405.
      View in: PubMed
    68. Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005 Oct; 8(4):337-48. PMID: 16226708.
      View in: PubMed
    69. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005 Aug 15; 106(4):1183-8. PMID: 15886328.
      View in: PubMed
    70. Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics. 2005 May; 85(5):600-7. PMID: 15820312.
      View in: PubMed
    71. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell. 2005 Apr; 7(4):291-3. PMID: 15837617.
      View in: PubMed
    72. Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K. Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med. 2005 Mar 21; 201(6):853-8. PMID: 15781578; PMCID: PMC2213101.
    73. Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood. 2005 Jul 01; 106(1):311-7. PMID: 15761018; PMCID: PMC1895116.
    74. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004 Dec; 6(6):547-52. PMID: 15607959.
      View in: PubMed
    75. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23. PMID: 14732923.
      View in: PubMed
    76. Braun BS, Shannon K. The sum is greater than the FGFR1 partner. Cancer Cell. 2004 Mar; 5(3):203-4. PMID: 15050910.
      View in: PubMed
    77. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004 Jun 01; 103(11):4243-50. PMID: 14982883.
      View in: PubMed
    78. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol. 2004 Jan; 11(1):44-50. PMID: 14676626.
      View in: PubMed
    79. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):597-602. PMID: 14699048; PMCID: PMC327193.
    80. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004 Mar 15; 103(6):2325-31. PMID: 14644997.
      View in: PubMed
    81. Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11630-5. PMID: 14500898; PMCID: PMC208809.
    82. Kratz CP, Antonietti L, Shannon KM, Dole MG, Friebert SE. Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1. J Pediatr Hematol Oncol. 2003 Apr; 25(4):343. PMID: 12679655.
      View in: PubMed
    83. Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials. Curr Opin Genet Dev. 2003 Feb; 13(1):84-9. PMID: 12573440.
      View in: PubMed
    84. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57. PMID: 12473573.
      View in: PubMed
    85. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell. 2002 Dec; 2(6):437-45. PMID: 12498712.
      View in: PubMed
    86. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell. 2002 Dec; 2(6):507-14. PMID: 12498719.
      View in: PubMed
    87. Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood. 2003 Mar 15; 101(6):2250-2. PMID: 12433685.
      View in: PubMed
    88. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell. 2002 Aug; 2(2):99-102. PMID: 12204529.
      View in: PubMed
    89. Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 2002 Jul 18; 21(31):4849-54. PMID: 12101424.
      View in: PubMed
    90. Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol. 2002 Jul; 9(4):308-15. PMID: 12042705.
      View in: PubMed
    91. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta. 2002 Mar 14; 1602(1):23-45. PMID: 11960693.
      View in: PubMed
    92. Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM. Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood. 2002 Jan 01; 99(1):372-4. PMID: 11756194.
      View in: PubMed
    Kevin's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP